Trimetazidine 20 mg №30 capsules


More info

Trimetazidine 20 mg №30 capsules

Trade name of the drug: Trimetazidine

International non-proprietary name:


Dosage Form:



One capsule contains:
Active ingredient - Trimetazidine dihydrochloride - 0.02 g.
Excipients: lactose (milk sugar), corn starch, povidone (low-molecular medical polyvinylpyrrolidone 12600 &№177; 2700), calcium stearate. Hard gelatin capsules: gelatin, water, titanium dioxide, iron dye yellow oxide, indigo carmine.


Hard gelatin capsules with white body, green lid.
The contents of the capsules - powder or compacted mass of white or almost white color, disintegrating when pressed.


It has an antihypoxic effect.
Directly affecting the cardiomyocytes and neurons of the brain, optimizes their metabolism and function. The cytoprotective effect is due to increased energy potential, activation of oxidative decarboxylation and rationalization of oxygen consumption (increased aerobic glycolysis and blockade of fatty acid oxidation). Supports myocardial contractility, prevents a decrease in the intracellular content of adenosine triphosphate (ATP) and phosphocreatine. Under conditions of acidosis, it normalizes the functioning of membrane ion channels, prevents the accumulation of calcium and sodium in cardiomyocytes, and normalizes the intracellular content of potassium ions. Reduces intracellular acidosis and elevated phosphate levels due to myocardial ischemia and reperfusion. Interferes with the damaging effects of free radicals, preserves the integrity of cell membranes, prevents activation of neutrophils in the ischemic zone, increases the duration of electrical potential, reduces the release of creatine phosphokinase from cells and the severity of ischemic myocardial damage.
Trimetazidine reduces the frequency of strokes, reduces the need for taking nitrates, after 2 weeks of admission, exercise tolerance increases, sharp fluctuations in blood pressure (BP) are reduced. Reduces dizziness and tinnitus. When vascular pathology of the eye improves the functional activity of the retina.


After taking the drug inside trimetazidine quickly and almost completely absorbed in the gastrointestinal tract. Bioavailability - 90%. The time to reach the maximum plasma concentration is 2 hours (the maximum concentration after a single dose of 20 mg of trimetazidine is about 55 ng / ml). Easily penetrates histohematogenous barriers. The half-life (T1 / 2) is 4.5-5 hours. Communication with plasma proteins - 16%. Excreted by the kidneys (about 60% unchanged).

Indications for use

Coronary heart disease: prevention of strokes (as part of complex therapy). Cochleovestibular disorders of the ischemic nature, such as dizziness, tinnitus, hearing loss. Chorioretinal vascular disorders.


Hypersensitivity to any component
Renal failure (creatinine clearance below 15 ml / min);
Severe abnormal liver function;
Lactation period;
Age up to 18 years (efficacy and safety have not been established);
Rare hereditary diseases: lactose intolerance, lactase deficiency, glucose-galactose malabsorption.

Use during pregnancy and lactation
The drug is contraindicated in pregnancy due to the lack of clinical data on the safety of its use. If necessary, the appointment of the drug during lactation should stop breastfeeding. It is not known whether trimetazidine is excreted in breast milk. In experimental studies, the teratogenic effect of trimetazidine has not been established.

Dosage and administration

Inside, during the meal.
The recommended dosage regimen is 2-3 capsules (40-60 mg) per day, in 2-3 doses.
The course of treatment is recommended by the doctor.

Side effect

Allergic reactions (pruritus), rarely - dyspeptic symptoms (nausea, vomiting, gastralgia).
Rarely - headache, feeling of palpitations.


Currently, no cases of overdose have been reported.

Interaction with other drugs are not described.

special instructions

Do not use for the relief of strokes. Not indicated for the initial course of treatment of unstable angina or myocardial infarction. If an attack of angina occurs, the treatment should be reviewed and adapted.Impact on the management of vehicles and mechanisms. Trimetazidine does not affect the ability to drive vehicles and perform work that require an increased rate of psychomotor reactions.

Release form

Capsules 20 mg.
10 or 20 capsules in a blister pack or 60 capsules in a polymer can. 3 or 5 blister packs of 20 capsules, or 3 or 6 blister packs of 10 capsules, or one can together with the instructions for use in a carton pack.

Storage conditions

List B.
In a dry, dark place at a temperature not higher than 25 ° C.
Keep out of the reach of children.

Shelf life

3 years.
Do not use after expiration date.

It is a pharmaceutical drug. Use only as directed by your doctor.